Compare DDD & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DDD | OCGN |
|---|---|---|
| Founded | 1986 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 459.0M | 474.8M |
| IPO Year | 2003 | 2014 |
| Metric | DDD | OCGN |
|---|---|---|
| Price | $3.30 | $1.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $4.75 | ★ $9.75 |
| AVG Volume (30 Days) | 1.9M | ★ 5.0M |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 109.79 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $386,902,000.00 | N/A |
| Revenue This Year | $2.48 | N/A |
| Revenue Next Year | $4.10 | $1,718.38 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.70 | $1.06 |
| 52 Week High | $4.12 | $2.73 |
| Indicator | DDD | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 49.28 | 27.69 |
| Support Level | $3.10 | N/A |
| Resistance Level | $3.63 | $1.93 |
| Average True Range (ATR) | 0.17 | 0.07 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 38.38 | 4.74 |
3D Systems Corp provide comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, manufacturing and applications engineering. Its solutions support applications in two key industry verticals: Healthcare Solutions provide surgical planning, implants, instrumentation, and medical education solutions to help medical device manufacturers and healthcare providers accelerate, and ultimately, transform healthcare, and Industrial Solutions which includes aerospace, defense, transportation and general manufacturing. The company operates in the Americas, EMEA, and APAC regions.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").